Head-to-head evidence
PHE885 vs Zevorcabtagene autoleucel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
PHE885
Developed by Novartis
NCT04318327 · Phase 1 · terminated
This is an early-phase, open-label study without randomization, blinding, or a control arm, in which every enrolled patient received the CAR-T therapy; its primary goal was to characterize safety and dose-limiting toxicity rather than to compare efficacy against a control treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Zevorcabtagene autoleucel
Marketed by CARsgen Therapeutics Holdings Limited
NCT03975907 · Phase 1/2 · status unknown
This study enrolled every patient into a single treatment group, with no comparison arm and no blinding, so there is no control group to judge the response rate against. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The registered phase 1 primary endpoint of this study is dose-limiting toxicity; the response rates shown are the phase 2 portion's primary endpoint (overall response rate).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PHE885's landscape · Zevorcabtagene autoleucel's landscape